Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | Phase
Phase 2
|
Date Added 2020-02-10 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04092673 |
TitleStudy of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Phase
Phase 1
|
Date Added 2019-09-17 |
Location
California, United States
Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
eFT226, eFT226 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06322693 |
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Phase
Phase 1
|
Date Added 2024-03-21 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Korea, Republic of Spain |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05141721 |
TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-12-02 |
Location
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleA Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | Phase
Phase 1
|
Date Added 2019-09-26 |
Location
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
CPI-0209, CPI-0209 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05205330 |
TitleA Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | Phase
Phase 1, Phase 2
|
Date Added 2022-01-25 |
Location
Italy
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AGEN2034, Balstilimab, CR6086 |
Tags
MSS/ MMRp
|
| NCT ID NCT05308446 |
TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | Phase
Phase 2
|
Date Added 2022-04-04 |
Location
Arizona, United States
California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT05201612 |
TitlePembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). | Phase
Phase 2
|
Date Added 2022-01-21 |
Location
Spain
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Unknown status
|
Drugs
Olaparib, Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03388190 |
TitleMETIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin | Phase
Phase 2
|
Date Added 2018-01-02 |
Location
Norway
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
FLOX, Nivolumab, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT03104439 |
TitleNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Phase
Phase 2
|
Date Added 2017-04-07 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab, Opdivo, Yervoy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
